Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses

Journal of Clinical Oncology

Volumn 33, Issue 9, 2015, Pages 1008-1014

  Blumenthal, Gideon M ^a   Karuri, Stella W ^a   Zhang, Hui ^a   Zhang, Lijun ^a   Khozin, Sean ^a   Kazandjian, Dickran ^a   Tang, Shenghui ^a   Sridhara, Rajeshwari ^a   Keegan, Patricia ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; BEVACIZUMAB; CETUXIMAB; CRIZOTINIB; ERLOTINIB; GEFITINIB; PACLITAXEL; PEMETREXED; VANDETANIB; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; UNITED STATES; ADOLESCENT; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; META ANALYSIS; MIDDLE AGED; MORTALITY; ODDS RATIO; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; STATISTICAL MODEL; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LINEAR MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 84927126291     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.0489     Document Type: Article

References (45)

1. Siegel R, Ma J, Zou Z, et al: Cancer statistics, 2014. CA Cancer J Clin 64:9-29, 2014
2. Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM): A genomics-based classification of human lung tumors. Sci Transl Med 5:209ra153, 2013
3. Pao W, Girard N: New driver mutations in non-small-cell lung cancer. Lancet Oncol 12:175-180, 2011
4. Kris MG, Johnson BE, Berry LD, et al: Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311:1998-2006, 2014
5. Khozin S, Blumenthal GM, Jiang X, et al: US Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations. Oncologist 19:774-779, 2014
6. Dungo RT, Keating GM: Afatinib: First global approval. Drugs 73:1503-1515, 2013
7. Malik SM, Maher VE, Bijwaard KE, et al: US Food and Drug Administration approval: Crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res 20:2029-2034, 2014
8. Chabner BA: Approval after phase I: Ceritinib runs the three-minute mile. Oncologist 19:577-578, 2014
9. US Food and Drug Administration: Guidance for industry: Clinical trial endpoints for the approval of nonsmall cell lung cancer drugs and biologics. http:// www.fda.gov/downloads/Drugs/Guidances/ UCM259421.pdf
10. Pazdur R: Endpoints for assessing drug activity in clinical trials. Oncologist 13:19-21, 2008
11. Johnson JR, Ning YM, Farrell A, et al: Accelerated approval of oncology products: The Food and Drug Administration experience. J Natl Cancer Inst 103:636-644, 2011
12. Burzykowski T, Molenberghs G, Buyse M: The validation of surrogate end points by using data from randomized clinical trials: A case-study in advanced colorectal cancer. J R Stat Soc A 167:103-124, 2004
13. Shaw AT, Kim DW, Nakagawa K, et al: Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385-2394, 2013
14. Sequist LV, Yang JC, Yamamoto N, et al: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31: 3327-3334, 2013
15. Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239-246, 2012
16. Socinski MA, Bondarenko I, Karaseva NA, et al: Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial. J Clin Oncol 30:2055-2062, 2012
17. Lynch TJ, Patel T, Dreisbach L, et al: Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28:911-917, 2010
18. Pirker R, Pereira JR, Szczesna A, et al: Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 373:1525-1531, 2009
19. Natale RB, Thongprasert S, Greco FA, et al: Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-smallcell lung cancer. J Clin Oncol 29:1059-1066, 2011
20. de Boer RH, Arrieta Ó, Yang CH, et al: Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: A randomized, double-blind phase III trial. J Clin Oncol 29: 1067-1074, 2011
21. Herbst RS, Sun Y, Eberhardt WE, et al: Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): A double-blind, randomised, phase 3 trial. Lancet Oncol 11:619-626, 2010
22. Kim ES, Hirsh V, Mok T, et al: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 372:1809-1818, 2008
23. Reck M, von Pawel J, Zatloukal P, et al: Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: Results from a randomised phase III trial (AVAiL). Ann Oncol 21: 1804-1809, 2010
24. Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
25. Sandler A, Gray R, Perry MC, et al: Paclitaxelcarboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 355:2542-2550, 2006
26. Hanna N, Shepherd FA, Fossella FV, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597, 2004
27. Anderson JR, Cain KC, Gelber RD: Analysis of survival by tumor response. J Clin Oncol 1:710-719, 1983
28. Sharma MR, Schilsky RL: Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol 9:208-214, 2011
29. Miller FG, Joffe S: Equipoise and the dilemma of randomized clinical trials. N Engl J Med 364:476-480, 2011
30. Kurzrock R, Stewart DJ: Equipoise abandoned? Randomization and clinical trials. Ann Oncol 24:2471-2474, 2013
31. Tsujino K, Kawaguchi T, Kubo A, et al: Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib. J Thorac Oncol 4:994-1001, 2009
32. Wang Y, Sung C, Dartois C, et al: Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther 86:167-174, 2009
33. Oxnard GR, Morris MJ, Hodi FS, et al: When progressive disease does not mean treatment failure: Reconsidering the criteria for progression. J Natl Cancer Inst 104:1534-1541, 2012
34. de Claro RA, McGinn K, Kwitkowski V, et al: US Food and Drug Administration approval summary: Brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 18:5845-5849, 2012
35. Dagher R, Cohen M, Williams G, et al: Approval summary: Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8:3034-3038, 2002
36. Herndon TM, Deisseroth A, Kaminskas E, et al: US Food and Drug Administration approval: Carfilzomib for the treatment of multiple myeloma. Clin Cancer Res 19:4559-4563, 2013
37. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390, 2008
38. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
39. Franz DN, Belousova E, Sparagana S, et al: Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381:125-132, 2013
40. Zhao B, Oxnard GR, Moskowitz CS, et al: A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res 16:4647-4653, 2010
41. Smith AD, Shah SN, Rini BI, et al: Morphology, attenuation, size, and structure (MASS) criteria: Assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 194:1470-1478, 2010
42. Wolchok JD, Hoos A, O'Day S, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 15:7412-7420, 2009
43. Jain RK, Lee JJ, Ng C, et al: Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol 30:2684-2690, 2012
44. Venook AP, Tabernero J: Progression-free survival: Helpful biomarker or clinically meaningless end point? J Clin Oncol [epub ahead of print on November 3, 2014]
45. Sharma MR, Gray E, Goldberg RM, et al: Resampling the N9741 trial to compare dynamic versus conventional end points in randomized phase II trials. J Clin Oncol [epub ahead of print on October 27, 2014]